{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-28T11:36:18.541457+00:00","company":{"ticker":"SKIN","cik":1818093,"company_name":"SkinHealth Systems Inc."},"pagination":{"limit":100,"returned":49,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Dr. Lawrence Groop, Kristin Groop, and Esthetic Education, LLC","detail":"asset_purchase","count":1,"first_seen":"2023-02-28T23:59:59+00:00","last_seen":"2023-02-28T23:59:59+00:00","evidence_fact_ids":[176012]},{"display_name":"JPMorgan Chase Bank, N.A.","detail":"credit_facility","count":1,"first_seen":"2022-11-15T23:59:59+00:00","last_seen":"2022-11-15T23:59:59+00:00","evidence_fact_ids":[196351]}],"lender":[{"display_name":"U.S. Bank Trust Company, National Association","detail":"senior_notes","count":1,"first_seen":"2025-05-27T23:59:59+00:00","last_seen":"2025-05-27T23:59:59+00:00","evidence_fact_ids":[83181]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"7e9bc4c6309e4e21f0202c7062449589ded3f796","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-06-16T20:08:55+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Advisory vote on the compensation of the named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"21,434,437","subject":null,"votes_abstain":"1,021,201","votes_against":"12,346,541","votes_for":"58,604,735","votes_withheld":null}]},"claim":"SkinHealth Systems Inc. shareholders approved Advisory vote on the compensation of the named executive officers at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory, non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the Proxy Statement, as follows: Votes For Votes Against Abstentions Broker Non-Votes 58,604,735 12,346,541 1,021,201 21,434,437","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-043539","anchor_url":"https://secwatch.observer/filing/0001628280-26-043539#claim-7e9bc4c6309e4e21f0202c7062449589ded3f796","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026043539/0001628280-26-043539-index.htm"},{"fact_type":"shareholder_vote","fact_key":"32623b2b683b4aae561c3b493e76b61d12a466c1","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-06-16T20:08:55+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"45,540","votes_against":"235,673","votes_for":"93,125,701","votes_withheld":null}]},"claim":"SkinHealth Systems Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent, registered public accounting firm for the fiscal year ending December 31, 2026, as follows: Votes For Votes Against Abstentions Broker Non-Votes 93,125,701 235,673 45,540 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-043539","anchor_url":"https://secwatch.observer/filing/0001628280-26-043539#claim-32623b2b683b4aae561c3b493e76b61d12a466c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026043539/0001628280-26-043539-index.htm"},{"fact_type":"shareholder_vote","fact_key":"54b5d98c70d97e319b9611bba62ff561b2987755","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-06-16T20:08:55+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of nine directors to serve for a one-year term expiring at the 2027 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"21,434,437","subject":"Brenton L. Saunders","votes_abstain":null,"votes_against":null,"votes_for":"64,713,062","votes_withheld":"7,259,415"},{"broker_non_votes":"21,434,437","subject":"Pedro Malha","votes_abstain":null,"votes_against":null,"votes_for":"70,933,549","votes_withheld":"1,038,928"},{"broker_non_votes":"21,434,437","subject":"E. Scott Beattie","votes_abstain":null,"votes_against":null,"votes_for":"61,017,737","votes_withheld":"10,954,740"},{"broker_non_votes":"21,434,437","subject":"Stephen J. Fanning","votes_abstain":null,"votes_against":null,"votes_for":"68,732,826","votes_withheld":"3,239,651"},{"broker_non_votes":"21,434,437","subject":"Michelle Kerrick","votes_abstain":null,"votes_against":null,"votes_for":"70,684,772","votes_withheld":"1,287,705"},{"broker_non_votes":"21,434,437","subject":"Brian Miller","votes_abstain":null,"votes_against":null,"votes_for":"56,555,107","votes_withheld":"15,417,370"},{"broker_non_votes":"21,434,437","subject":"Doug Schillinger","votes_abstain":null,"votes_against":null,"votes_for":"61,107,166","votes_withheld":"10,865,311"},{"broker_non_votes":"21,434,437","subject":"Sachin Shridharani, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"71,317,162","votes_withheld":"655,315"},{"broker_non_votes":"21,434,437","subject":"Kenneth Tripp","votes_abstain":null,"votes_against":null,"votes_for":"71,078,056","votes_withheld":"894,421"}]},"claim":"SkinHealth Systems Inc. shareholders approved Election of nine directors to serve for a one-year term expiring at the 2027 annual meeting at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders elected the nine directors listed below, each to serve for a term of one year, expiring at the Company's 2027 annual meeting of stockholders or until his or her successor is duly appointed or elected and qualified or until his or her earlier death, resignation, or removal from office, as follows: Nominees Votes For Votes Withheld Broker Non-Votes Brenton L. Saunders 64,713,062 7,259,415 21,434,437 Pedro Malha 70,933,549 1,038,928 21,434,437 E. Scott Beattie 61,017,737 10,954,740 21,434,437 Stephen J. Fanning 68,732,826 3,239,651 21,434,437 Michelle Kerrick 70,684,772 1,287,705 21,434,437 Brian Miller 56,555,107 15,417,370 21,434,437 Doug Schillinger 61,107,166 10,865,311 21,434,437 Sachin Shridharani, M.D. 71,317,162 655,315 21,434,437 Kenneth Tripp 71,078,056 894,421 21,434,437","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-043539","anchor_url":"https://secwatch.observer/filing/0001628280-26-043539#claim-54b5d98c70d97e319b9611bba62ff561b2987755","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026043539/0001628280-26-043539-index.htm"},{"fact_type":"executive_change","fact_key":"74371d8624","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-05-21T20:40:52+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2026-05-06","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ronald Menezes was terminated as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"terminated Ronald Menezes’ employment as Chief Revenue Officer of the Company without cause, effective as of May 6, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-037340","anchor_url":"https://secwatch.observer/filing/0001628280-26-037340#claim-74371d8624","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026037340/0001628280-26-037340-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"0291182f2817447575f46bd028a5236d7d356cab","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-05-12T20:08:38+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-11-04","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00 per share for at least 10 consecutive business days","notice_date":"2026-05-08","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"SkinHealth Systems Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"May 8, 2026, SkinHealth Systems Inc., a Delaware corporation (the “Company”), received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying t","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-034101","anchor_url":"https://secwatch.observer/filing/0001628280-26-034101#claim-0291182f2817447575f46bd028a5236d7d356cab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026034101/0001628280-26-034101-index.htm"},{"fact_type":"earnings_release","fact_key":"9e24e8be7351d0bc85d9c1db0e2dcab8b26de6dc","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"preliminary_results","revenue_text":null},"claim":"SkinHealth Systems Inc. updated its first quarter ended March 31, 2026 guidance (lowered).","evidence_excerpt":"On May 7, 2026, SkinHealth Systems Inc. (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-032099","anchor_url":"https://secwatch.observer/filing/0001628280-26-032099#claim-9e24e8be7351d0bc85d9c1db0e2dcab8b26de6dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026032099/0001628280-26-032099-index.htm"},{"fact_type":"executive_change","fact_key":"b451ee642c","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2026-05-05","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ronald Menezes was terminated as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"On May 5, 2026, the Board of Directors of SkinHealth Systems Inc. (the “Company”) terminated Mr. Ronald Menezes' employment as Chief Revenue Officer of the Company without cause, effective as of May 5, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-031243","anchor_url":"https://secwatch.observer/filing/0001628280-26-031243#claim-b451ee642c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026031243/0001628280-26-031243-index.htm"},{"fact_type":"governance_change","fact_key":"c4b72450ffce29ed275f3f169c26359bc0652248","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-04-22T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-22","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to reflect name change and provide updates including simplifying registered office description, updating certificate of incorporation reference, clarifying stockholder list availability, adding Rule 14a-19 compliance requirement, revising director terms, revising Chairman"},"claim":"SkinHealth Systems Inc.: Amended and restated bylaws to reflect name change and provide updates including simplifying registered office description, updating certificate of incorporation reference, clarifying stockholder list availability, adding Rule 14a-19 compliance requirement, revising director terms, revising Chairman (effective 2026-04-22).","evidence_excerpt":"The Company also amended and restated its bylaws (the “Second Amended and Restated Bylaws”) effective April 22, 2026, to reflect the Name Change and to provide for certain updates, including: (i) simplifying the description of the registered office to provide that the registered office shall be located at the office of the corporation or individual acting as the Company’s registered agent in Delaware, as designated from time to time in the manner provided by law, and removing the alternative reference to the principal place of business of the Company in the State of Delaware; (ii) updating the defined term for the Company’s certificate of incorporation to refer to the certificate of incorporation as amended, restated, supplemented or otherwise modified from time to time; (iii) clarifying that the stockholder list required to be made available prior to each stockholders’ meeting must be open for examination during the 10-day period ending before (rather than prior to) such meeting; (iv)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-026555","anchor_url":"https://secwatch.observer/filing/0001628280-26-026555#claim-c4b72450ffce29ed275f3f169c26359bc0652248","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026026555/0001628280-26-026555-index.htm"},{"fact_type":"governance_change","fact_key":"bc6817faf16c9a35bdf1ef79c3ac0f2f5d30b565","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-04-22T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-04-22","item_codes_triggered":["5.03"],"summary_text":"Changed company name to SkinHealth Systems Inc. via third certificate of amendment"},"claim":"SkinHealth Systems Inc.: Changed company name to SkinHealth Systems Inc. via third certificate of amendment (effective 2026-04-22).","evidence_excerpt":"On April 21, 2026, the Company filed with the Secretary of State of the State of Delaware (the “Secretary of State”) a third certificate of amendment (the “Charter Amendment”) to the Company’s second amended and restated certificate of incorporation (the “Second Amended and Restated Certificate”) to change the Company’s name to “SkinHealth Systems Inc.” (the “Name Change”). The Charter Amendment became effective at 12:01 a.m. E.T. on April 22, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-026555","anchor_url":"https://secwatch.observer/filing/0001628280-26-026555#claim-bc6817faf16c9a35bdf1ef79c3ac0f2f5d30b565","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026026555/0001628280-26-026555-index.htm"},{"fact_type":"earnings_release","fact_key":"fa1bb72ca9cc47a7828949daf821ced498b18787","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal quarter and year ended December 31, 2025","report_date":"2026-03-12","result_type":"reported_results","revenue_text":null},"claim":"SkinHealth Systems Inc. reported financial results for fiscal quarter and year ended December 31, 2025.","evidence_excerpt":"On March 12, 2026, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter and year ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-017222","anchor_url":"https://secwatch.observer/filing/0001628280-26-017222#claim-fa1bb72ca9cc47a7828949daf821ced498b18787","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828026017222/0001628280-26-017222-index.htm"},{"fact_type":"governance_change","fact_key":"eb9c8e8036d39b4ec328477878489db2b3a7d8f3","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2025-08-01T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-31","item_codes_triggered":["5.03"],"summary_text":"Corrected a scrivener's error in the Amended Certificate to allow removal of directors with or without cause, instead of only for cause."},"claim":"SkinHealth Systems Inc.: Corrected a scrivener's error in the Amended Certificate to allow removal of directors with or without cause, instead of only for cause (effective 2025-07-31).","evidence_excerpt":"On July 31, 2025, The Beauty Health Company (the \"Company\") filed a Certificate of Correction (the \"Certificate of Correction\") to its Second Amended and Restated Certificate of Incorporation","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-037230","anchor_url":"https://secwatch.observer/filing/0001628280-25-037230#claim-eb9c8e8036d39b4ec328477878489db2b3a7d8f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828025037230/0001628280-25-037230-index.htm"},{"fact_type":"debt_financing","fact_key":"98f111b2646fb78c4c2722b11ff3407720deed97","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2025-05-27T23:59:59+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2025-05-27","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"7.95% per annum","item_codes_triggered":["2.03"],"maturity_text":"November 15, 2028","principal_text":"$250,000,000 principal amount"},"claim":"SkinHealth Systems Inc. incurred senior notes of $250,000,000 principal amount with U.S. Bank Trust Company, National Association at 7.95% per annum maturing November 15, 2028.","evidence_excerpt":"issued $250,000,000 principal amount of its 7.95% Convertible Senior Secured Notes due 2028","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-004033","anchor_url":"https://secwatch.observer/filing/0001683168-25-004033#claim-98f111b2646fb78c4c2722b11ff3407720deed97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000168316825004033/0001683168-25-004033-index.htm"},{"fact_type":"executive_change","fact_key":"44a2a68789","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2025-02-28T23:59:59+00:00","payload":{"action":"designated","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-25","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ronald Menezes changed role as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"Due to this determination, the Board designated Mr. Menezes as an executive officer, as that term is defined in 17 C.F.R. § 240.3b-7 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), thus making Mr. Menezes an executive officer subject to Section 16 of the Exchange Act (a \"Section 16 Officer\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-25-009050","anchor_url":"https://secwatch.observer/filing/0001628280-25-009050#claim-44a2a68789","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828025009050/0001628280-25-009050-index.htm"},{"fact_type":"executive_change","fact_key":"c0c9d4d826","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-10-14","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Daniel Watson was terminated as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"On October 8, 2024, the Board of Directors of the Company terminated Daniel Watson’s employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024 (the \"Termination Date\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-047098","anchor_url":"https://secwatch.observer/filing/0001628280-24-047098#claim-c0c9d4d826","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024047098/0001628280-24-047098-index.htm"},{"fact_type":"executive_change","fact_key":"3252de0406","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-10-14","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Daniel Watson was terminated as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"On October 8, 2024, the Board of Directors (the \"Board\") of The Beauty Health Company (the \"Company\") terminated Daniel Watson's employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-042835","anchor_url":"https://secwatch.observer/filing/0001628280-24-042835#claim-3252de0406","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024042835/0001628280-24-042835-index.htm"},{"fact_type":"executive_change","fact_key":"62ded65abb","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-08-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-26","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Julius Few resigned as director at SkinHealth Systems Inc..","evidence_excerpt":"On August 26, 2024, Dr. Julius Few notified the board of directors (the \"Board\") of The Beauty Health Company (the \"Company\") of his decision to resign as a director of the Company, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-24-038962","anchor_url":"https://secwatch.observer/filing/0001628280-24-038962#claim-62ded65abb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024038962/0001628280-24-038962-index.htm"},{"fact_type":"earnings_release","fact_key":"81ef7954118c5680b60ef1ee8dbb21d56a5b06a6","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"SkinHealth Systems Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its quarter ended March 31, 2024.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001628280-24-022209","anchor_url":"https://secwatch.observer/filing/0001628280-24-022209#claim-81ef7954118c5680b60ef1ee8dbb21d56a5b06a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024022209/0001628280-24-022209-index.htm"},{"fact_type":"executive_change","fact_key":"42af95633f","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"action":"mutually agreed to terminate","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-09","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Brad Hauser departed as Chief Operating Officer at SkinHealth Systems Inc..","evidence_excerpt":"On April 8, 2024, the Company and Brad Hauser mutually agreed to terminate Mr. Hauser’s employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-019980","anchor_url":"https://secwatch.observer/filing/0001628280-24-019980#claim-42af95633f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024019980/0001628280-24-019980-index.htm"},{"fact_type":"executive_change","fact_key":"dd083143b0","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-04-09T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-09","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Brad Hauser was terminated as Chief Operating Officer at SkinHealth Systems Inc..","evidence_excerpt":"On April 8, 2024, The Beauty Health Company (the \"Company\") and Brad Hauser mutually agreed to terminate Mr. Hauser’s employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-015457","anchor_url":"https://secwatch.observer/filing/0001628280-24-015457#claim-dd083143b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024015457/0001628280-24-015457-index.htm"},{"fact_type":"executive_change","fact_key":"befb4f5705","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-04-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-04-08","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Marla Beck was appointed as President and Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"the Company’s Board of Directors (the “Board”) had unanimously approved Marla Beck to be the Company’s President and Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-015295","anchor_url":"https://secwatch.observer/filing/0001628280-24-015295#claim-befb4f5705","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024015295/0001628280-24-015295-index.htm"},{"fact_type":"earnings_release","fact_key":"24ef4c190ff2ed25612570aeaa4ddadc9905d317","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(100.1) million","period_text":"the fiscal year ended December 31, 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$398.0 million"},"claim":"SkinHealth Systems Inc. reported the fiscal year ended December 31, 2023 results: revenue $398.0 million, net income $(100.1) million.","evidence_excerpt":"with its disclosure obligations under Regulation FD. \n\n--- EX-99.1 (EX-99.1) ---\n\nBeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results Delivers net sales of $398 million for the full year and $96.8 million for the fourth quarter driven by growth across international markets Long Beach, Calif., March 12, 2024 – The Beauty Health Company (NASDAQ:","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-010538","anchor_url":"https://secwatch.observer/filing/0001628280-24-010538#claim-24ef4c190ff2ed25612570aeaa4ddadc9905d317","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024010538/0001628280-24-010538-index.htm"},{"fact_type":"earnings_release","fact_key":"47bc954876888e4c590e5714c2da7eab46dd9e3e","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(9.4) million","period_text":"the fourth quarter ended December 31, 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$96.8 million"},"claim":"SkinHealth Systems Inc. reported the fourth quarter ended December 31, 2023 results: revenue $96.8 million, net income $(9.4) million.","evidence_excerpt":"Regulation FD. \n\n--- EX-99.1 (EX-99.1) ---\n\nBeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results Delivers net sales of $398 million for the full year and $96.8 million for the fourth quarter driven by growth across international markets Long Beach, Calif., March 12, 2024 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-010538","anchor_url":"https://secwatch.observer/filing/0001628280-24-010538#claim-47bc954876888e4c590e5714c2da7eab46dd9e3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024010538/0001628280-24-010538-index.htm"},{"fact_type":"executive_change","fact_key":"12b5863d4e","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-12-14T23:59:59+00:00","payload":{"action":"terminated without cause","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Andrew Stanleick departed as Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"Mr. Stanleick’s termination from his position as Chief Executive Officer of the Company without cause","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-041578","anchor_url":"https://secwatch.observer/filing/0001628280-23-041578#claim-12b5863d4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023041578/0001628280-23-041578-index.htm"},{"fact_type":"restructuring_charge","fact_key":"f6efd3766ca4d9299f237a73e61ada70e846e8a7","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-11-16T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $5.1 million","effective_date":"2023-11-14","event_type":"restructuring","headcount_text":"reduce its current global workforce by 10%, including 95 employees","item_codes_triggered":["2.05"]},"claim":"SkinHealth Systems Inc. announced a restructuring with charges of approximately $5.1 million (reduce its current global workforce by 10%, including 95 employees).","evidence_excerpt":"of claims against the Company. In connection with this workforce reduction, the Company estimates that it will incur charges in the fourth quarter of 2023 of approximately $5.1 million related to notice pay, cash severance payments, and other employee-related separation costs. The Company expects that the majority of these charges will be incurred in the fourth","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-039265","anchor_url":"https://secwatch.observer/filing/0001628280-23-039265#claim-f6efd3766ca4d9299f237a73e61ada70e846e8a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023039265/0001628280-23-039265-index.htm"},{"fact_type":"executive_change","fact_key":"b5d253f153","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-11-20","interim":true,"role":"interim chief executive officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Marla Beck was appointed as interim chief executive officer at SkinHealth Systems Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of The Beauty Health Company (the “Company”) appointed Marla Beck, age 53, as interim chief executive officer of the Company (the “Interim CEO”), for a 6-month term (the “Term”) effective November 20, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-038598","anchor_url":"https://secwatch.observer/filing/0001628280-23-038598#claim-b5d253f153","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023038598/0001628280-23-038598-index.htm"},{"fact_type":"executive_change","fact_key":"7ee25bc086","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"action":"step down","action_category":"departure","departure_tone":"routine","effective_date":"2023-11-19","interim":false,"role":"chief executive officer","role_category":"ceo","successor_name":"Marla Beck","successor_named":true},"claim":"Andrew Stanleick departed as chief executive officer at SkinHealth Systems Inc..","evidence_excerpt":"Andrew Stanleick, who will step down from the role of chief executive officer of the Company, effective as of November 19, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-038598","anchor_url":"https://secwatch.observer/filing/0001628280-23-038598#claim-7ee25bc086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023038598/0001628280-23-038598-index.htm"},{"fact_type":"earnings_release","fact_key":"9cefe08fa5ee2b8f4eef0989047e4cba76f7dfc3","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(73.8)","period_text":"third quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":"$97.4 million"},"claim":"SkinHealth Systems Inc. reported third quarter ended September 30, 2023 results: revenue $97.4 million, net income $(73.8). Guidance reaffirmed.","evidence_excerpt":"revenue and incurs restructuring charges for device upgrades Delivers net sales of $97.4 million driven by double digit growth in APAC and EMEA Long Beach, Calif., November 13, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-038610","anchor_url":"https://secwatch.observer/filing/0001628280-23-038610#claim-9cefe08fa5ee2b8f4eef0989047e4cba76f7dfc3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023038610/0001628280-23-038610-index.htm"},{"fact_type":"earnings_release","fact_key":"2efbb67163dc6a8b39839501a69aa62ae0dedb39","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$3.4 million","period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-09","result_type":"reported_results","revenue_text":"$117.5 million"},"claim":"SkinHealth Systems Inc. reported the second quarter ended June 30, 2023 results: revenue $117.5 million, net income $3.4 million. Guidance reaffirmed.","evidence_excerpt":"For the quarter, net sales of $117.5 million increased +13% year-over-year, or +32% excluding trade-ups, continuing a trend of double-digit quarterly growth. Net income was $3.4 million, and adjusted EBITDA margin was 15.1% for the quarter. On the momentum, the Company re-affirms its 2023 net sales and long-term 2025 financial guidance, and refines its 2023 adjusted EBITDA margin to a more precise 18%-19% range.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-028406","anchor_url":"https://secwatch.observer/filing/0001628280-23-028406#claim-2efbb67163dc6a8b39839501a69aa62ae0dedb39","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028406/0001628280-23-028406-index.htm"},{"fact_type":"executive_change","fact_key":"f234b62e02","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2023-08-10","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Michael Monahan","successor_named":true},"claim":"Liyuan Woo departed as Chief Financial Officer at SkinHealth Systems Inc..","evidence_excerpt":"Mr. Monahan will replace Liyuan Woo, who will step down from the role of Chief Financial Officer, effective as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-028404","anchor_url":"https://secwatch.observer/filing/0001628280-23-028404#claim-f234b62e02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028404/0001628280-23-028404-index.htm"},{"fact_type":"executive_change","fact_key":"c15f7785e3","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-10","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Michael Monahan was appointed as Chief Financial Officer at SkinHealth Systems Inc..","evidence_excerpt":"On August 3, 2023, the Board of Directors (the “Board”) of The Beauty Health Company (the “Company”) appointed Michael Monahan, age 51, as Chief Financial Officer of the Company, effective August 10, 2023 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-028404","anchor_url":"https://secwatch.observer/filing/0001628280-23-028404#claim-c15f7785e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028404/0001628280-23-028404-index.htm"},{"fact_type":"shareholder_vote","fact_key":"09af5a43f82e692844da5a79102781f27144bc5e","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-14","outcome":"passed","proposal_text":"Advisory Vote on the Compensation of the Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"7,996,142","subject":null,"votes_abstain":"23,712","votes_against":"425,849","votes_for":"113,454,143","votes_withheld":null}]},"claim":"SkinHealth Systems Inc. shareholders approved Advisory Vote on the Compensation of the Named Executive Officers at the 2023-06-14 meeting.","evidence_excerpt":"Proposal No. 3 : Advisory Vote on the Compensation of the Named Executive Officers The Company’s stockholders approved, on an advisory, non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the Proxy Statement, as follows: Votes For Votes Against Abstentions Broker Non-Votes 113,454,143 425,849 23,712 7,996,142","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-022890","anchor_url":"https://secwatch.observer/filing/0001628280-23-022890#claim-09af5a43f82e692844da5a79102781f27144bc5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023022890/0001628280-23-022890-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f9e32c2bb80cbfdda19b1f3c1a331cb88c4c62b4","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-14","outcome":"passed","proposal_text":"Ratification of Appointment of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"4,846","votes_against":"485,100","votes_for":"121,409,900","votes_withheld":null}]},"claim":"SkinHealth Systems Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.","evidence_excerpt":"Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent, registered public accounting firm for the fiscal year ending December 31, 2023, as follows: Votes For Votes Against Abstentions Broker Non-Votes 121,409,900 485,100 4,846 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-022890","anchor_url":"https://secwatch.observer/filing/0001628280-23-022890#claim-f9e32c2bb80cbfdda19b1f3c1a331cb88c4c62b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023022890/0001628280-23-022890-index.htm"},{"fact_type":"shareholder_vote","fact_key":"76b3cf46477224a5d1b9002d3cdf586ea823d5bc","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-14","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"7,996,142","subject":"Michael D. Capellas","votes_abstain":null,"votes_against":null,"votes_for":"82,219,150","votes_withheld":"31,684,554"},{"broker_non_votes":"7,996,142","subject":"Dr. Julius Few","votes_abstain":null,"votes_against":null,"votes_for":"91,102,606","votes_withheld":"22,801,098"},{"broker_non_votes":"7,996,142","subject":"Brian Miller","votes_abstain":null,"votes_against":null,"votes_for":"90,921,951","votes_withheld":"22,981,753"}]},"claim":"SkinHealth Systems Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.","evidence_excerpt":"Proposal No. 1 : Election of Class II Directors The Company’s stockholders re-elected each of the three Class II directors listed below, each to hold office for a period of three years until the Company’s 2026 annual meeting of stockholders, or until his successor is duly appointed or elected and qualified, subject to prior death, resignation, or removal, as follows: Nominees Votes For Votes Withheld Broker Non-Votes Michael D. Capellas 82,219,150 31,684,554 7,996,142 Dr. Julius Few 91,102,606 22,801,098 7,996,142 Brian Miller 90,921,951 22,981,753 7,996,142","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-022890","anchor_url":"https://secwatch.observer/filing/0001628280-23-022890#claim-76b3cf46477224a5d1b9002d3cdf586ea823d5bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023022890/0001628280-23-022890-index.htm"},{"fact_type":"earnings_release","fact_key":"100a9a735f2db40300321fd28f90c7af4a7cdf04","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-05-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$(22.3) million","period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-10","result_type":"reported_results","revenue_text":"$86.3 million"},"claim":"SkinHealth Systems Inc. reported the first quarter ended March 31, 2023 results: revenue $86.3 million, net income $(22.3) million. Guidance raised.","evidence_excerpt":"BeautyHealth Reports First Quarter 2023 Financial Results\nOn strong consumer demand, delivers double-digit net sales growth in line with 2023 plan\nRaises fiscal 2023 net sales guidance\nLong Beach, Calif., May 10, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2023. For the quarter, net sales of $86.3 million increased +14% year-over-year, continuing a trend of double-digit quarterly growth. On the momentum, the Company raises 2023 net sales guidance and reaffirms 2023 EBITDA margin and 2025 long-term targets. The quarter was underpinned by continued strong consumer demand for Hydrafacial treatments, with +21% year-over-year consumables net sales growth globally. Of note, consumables net sales grew +34% year-over-year in the Americas and +13% in EMEA. Excluding $1.2 million of Q1 2022 consumables net sales in Russia, growth in EMEA was +35%. In APAC, consumables net sales declin","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-017025","anchor_url":"https://secwatch.observer/filing/0001628280-23-017025#claim-100a9a735f2db40300321fd28f90c7af4a7cdf04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023017025/0001628280-23-017025-index.htm"},{"fact_type":"executive_change","fact_key":"ea2d5b2154","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-04-19T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-04-19","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Brad Hauser changed role as Chief Operating Officer at SkinHealth Systems Inc..","evidence_excerpt":"On April 19, 2023, The Beauty Health Company (the “Company”) promoted Brad Hauser to the position of Chief Operating Officer of the Company, effective as of April 19, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001818093-23-000014","anchor_url":"https://secwatch.observer/filing/0001818093-23-000014#claim-ea2d5b2154","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809323000014/0001818093-23-000014-index.htm"},{"fact_type":"material_agreement","fact_key":"f26ee6b8f0a415106bc9a758532dc27ef3b5542a","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Stock Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Dr. Lawrence Groop, Kristin Groop, and Esthetic Education, LLC","effective_date":"2023-02-27","item_codes_triggered":["1.01"],"value_text":"$16,300,000"},"claim":"SkinHealth Systems Inc. entered into Stock Purchase Agreement with Dr. Lawrence Groop, Kristin Groop, and Esthetic Education, LLC valued at $16,300,000 (effective 2023-02-27).","evidence_excerpt":"On February 27, 2023, Edge Systems Intermediate, LLC (the “Buyer”), an indirect, wholly-owned subsidiary of The Beauty Health Company (the “Company”), entered into that certain Stock Purchase Agreement (the “Purchase Agreement”), with Dr. Lawrence Groop (“Seller”) and Kristin Groop (“Mrs. Groop”), and Esthetic Education, LLC, a company wholly-owned by Mrs. Groop (“EE LLC” and collectively with Seller and Mrs. Groop, the “Seller Parties” and each, a “Seller Party”). Pursuant to the Purchase Agreement, Seller will sell to Buyer, and Buyer will purchase from Seller, all of the outstanding shares of Esthetic Medical Inc. (“EMI”), a company wholly-owned by Dr. Groop (the “EMI Shares”), upon the terms and subject to the conditions of the Purchase Agreement (such purchase and sale, together with the other transactions contemplated by the Purchase Agreement, the “Transactions”). In exchange for the EMI Shares, Buyer will pay or cause to be paid to Seller total consideration of $16,300,000","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-23-000003","anchor_url":"https://secwatch.observer/filing/0001818093-23-000003#claim-f26ee6b8f0a415106bc9a758532dc27ef3b5542a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809323000003/0001818093-23-000003-index.htm"},{"fact_type":"earnings_release","fact_key":"cea0249d76b52fc14ed06bebcc84d1bb7e381335","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$3.8 million","period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":"$98.1 million"},"claim":"SkinHealth Systems Inc. reported the fourth quarter ended December 31, 2022 results: revenue $98.1 million, net income $3.8 million. Guidance reaffirmed.","evidence_excerpt":"Full year 2022 net sales of $365.9 million increased +41% relative to 2021, and fourth quarter net sales of $98.1 million increased +26%, revealing consistent mid-to-high double-digit quarterly growth year-over-year. The Company delivered net income of $44.4 million and adjusted EBITDA of $47.7 million for the full year, up +46% relative to 2021, and net income of $3.8 million and adjusted EBITDA of $16.3 million for the fourth quarter, up +92% relative to the fourth quarter of 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818093-23-000004","anchor_url":"https://secwatch.observer/filing/0001818093-23-000004#claim-cea0249d76b52fc14ed06bebcc84d1bb7e381335","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809323000004/0001818093-23-000004-index.htm"},{"fact_type":"earnings_release","fact_key":"194b1ec62666ecf440748d71c5d92bf6e4ec597a","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$44.4 million","period_text":"the full year ended December 31, 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":"$365.9 million"},"claim":"SkinHealth Systems Inc. reported the full year ended December 31, 2022 results: revenue $365.9 million, net income $44.4 million. Guidance reaffirmed.","evidence_excerpt":"Full year 2022 net sales of $365.9 million increased +41% relative to 2021, and fourth quarter net sales of $98.1 million increased +26%, revealing consistent mid-to-high double-digit quarterly growth year-over-year. The Company delivered net income of $44.4 million and adjusted EBITDA of $47.7 million for the full year, up +46% relative to 2021, and net income of $3.8 million and adjusted EBITDA of $16.3 million for the fourth quarter, up +92% relative to the fourth quarter of 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818093-23-000004","anchor_url":"https://secwatch.observer/filing/0001818093-23-000004#claim-194b1ec62666ecf440748d71c5d92bf6e4ec597a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809323000004/0001818093-23-000004-index.htm"},{"fact_type":"executive_change","fact_key":"d7718a6eb7","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2023-01-06T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-01-01","interim":false,"role":"Chief Revenue Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Daniel Watson changed role as Chief Revenue Officer at SkinHealth Systems Inc..","evidence_excerpt":"On January 5, 2023, The Beauty Health Company (the “Company”) promoted its current Executive Vice President of Sales (Americas), Daniel Watson, to the position of Chief Revenue Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-23-000002","anchor_url":"https://secwatch.observer/filing/0001818093-23-000002#claim-d7718a6eb7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809323000002/0001818093-23-000002-index.htm"},{"fact_type":"material_agreement","fact_key":"1b0625392937950fabe7d38d9e706f33a90cd979","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-11-15T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended and Restated Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2022-11-14","item_codes_triggered":["1.01"],"value_text":"$50 million revolving credit facility"},"claim":"SkinHealth Systems Inc. amended Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. valued at $50 million revolving credit facility (effective 2022-11-14).","evidence_excerpt":"On November 14, 2022, The Beauty Health Company, a Delaware corporation (as successor by assumption to HydraFacial LLC (formerly known as Edge Systems LLC), a California limited liability company (“HydraFacial” and the “Initial Borrower”) (the “Borrower,” “Company,” “we” or “our”), as borrower, entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A. (the “Administrative Agent”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818093-22-000177","anchor_url":"https://secwatch.observer/filing/0001818093-22-000177#claim-1b0625392937950fabe7d38d9e706f33a90cd979","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000177/0001818093-22-000177-index.htm"},{"fact_type":"earnings_release","fact_key":"b19d907939cdff9ed8cfc99e300a8b16032b79fe","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2022","report_date":"2022-11-08","result_type":"guidance_update","revenue_text":"$360 million to $365 million"},"claim":"SkinHealth Systems Inc. reported full year 2022 results: revenue $360 million to $365 million. Guidance raised.","evidence_excerpt":"On continued momentum and strong provider and consumer demand, the Company raised its 2022 net sales guidance to $360 million to $365 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-22-000166","anchor_url":"https://secwatch.observer/filing/0001818093-22-000166#claim-b19d907939cdff9ed8cfc99e300a8b16032b79fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000166/0001818093-22-000166-index.htm"},{"fact_type":"earnings_release","fact_key":"169aeeb2a0aa60711c7bd04aaae1c1e75ba13793","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":null},"claim":"SkinHealth Systems Inc. updated its third quarter ended September 30, 2022 guidance (raised).","evidence_excerpt":"BeautyHealth Reports Third Quarter 2022 Financial Results Net sales beat expectations for seventh consecutive quarter Company raises 2022 net sales guidance on continued momentum and strong demand, revises adjusted EBITDA guidance against a complex macro backdrop Long Beach, Calif., November 8, 2022 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001818093-22-000166","anchor_url":"https://secwatch.observer/filing/0001818093-22-000166#claim-169aeeb2a0aa60711c7bd04aaae1c1e75ba13793","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000166/0001818093-22-000166-index.htm"},{"fact_type":"executive_change","fact_key":"d0b6136d0f","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-08-26T23:59:59+00:00","payload":{"action":"transitioned out","action_category":"departure","departure_tone":"routine","effective_date":"2022-08-25","interim":false,"role":"President of EMEA","role_category":"president","successor_name":null,"successor_named":false},"claim":"Stephan Becker changed role as President of EMEA at SkinHealth Systems Inc..","evidence_excerpt":"Effective August 25, 2022, Stephan Becker, President of EMEA of The Beauty Health Company (the “Company”), has transitioned out of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-22-000145","anchor_url":"https://secwatch.observer/filing/0001818093-22-000145#claim-d0b6136d0f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000145/0001818093-22-000145-index.htm"},{"fact_type":"executive_change","fact_key":"051cc28cd7","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-06-10T23:59:59+00:00","payload":{"action":"transitioned out","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2022-06-08","interim":false,"role":"President of APAC","role_category":"president","successor_name":null,"successor_named":false},"claim":"Indra Pamamull changed role as President of APAC at SkinHealth Systems Inc..","evidence_excerpt":"Effective June 8, 2022, Indra Pamamull, President of APAC of The Beauty Health Company (the “Company”), has transitioned out of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-22-000101","anchor_url":"https://secwatch.observer/filing/0001818093-22-000101#claim-051cc28cd7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000101/0001818093-22-000101-index.htm"},{"fact_type":"executive_change","fact_key":"b865f7ed98","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-06-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Marla Beck was appointed as Director at SkinHealth Systems Inc..","evidence_excerpt":"the Board appointed Ms. Marla Beck to the Board as a Class III Director, effective as of June 6, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001818093-22-000083","anchor_url":"https://secwatch.observer/filing/0001818093-22-000083#claim-b865f7ed98","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000083/0001818093-22-000083-index.htm"},{"fact_type":"executive_change","fact_key":"acee3e1c66","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-01-20T23:59:59+00:00","payload":{"action":"ceased to serve","action_category":"role_change","departure_tone":"routine","effective_date":"2022-02-07","interim":false,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":"Andrew Stanleick","successor_named":true},"claim":"Brenton L. Saunders changed role as Interim Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"Upon Mr. Stanleick commencing employment as the Company’s Chief Executive Officer, Brenton L. Saunders, the current interim Chief Executive Officer of the Company and the Executive Chairman of the Board, will cease to serve as interim Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001818093-22-000017","anchor_url":"https://secwatch.observer/filing/0001818093-22-000017#claim-acee3e1c66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000017/0001818093-22-000017-index.htm"},{"fact_type":"executive_change","fact_key":"c6566c3604","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2022-01-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-07","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Andrew Stanleick was appointed as President and Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"On January 20, 2022, The Beauty Health Company (the “Company”) announced the appointment of Andrew Stanleick to serve as its President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective as of February 7, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001818093-22-000017","anchor_url":"https://secwatch.observer/filing/0001818093-22-000017#claim-c6566c3604","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000017/0001818093-22-000017-index.htm"},{"fact_type":"executive_change","fact_key":"bca8d5b517","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2021-11-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-01","interim":true,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Brenton L. Saunders was appointed as Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"The Board will appoint Brenton L. Saunders, currently Executive Chairman of the Board, to serve as the Company’s Chief Executive Officer, effective January 1, 2022, until a permanent successor is identified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-21-000105","anchor_url":"https://secwatch.observer/filing/0001818093-21-000105#claim-bca8d5b517","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000105/0001818093-21-000105-index.htm"},{"fact_type":"executive_change","fact_key":"bfdedb1d69","cik":1818093,"ticker":"SKIN","company_name":"SkinHealth Systems Inc.","filed_at":"2021-11-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-12-31","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Brenton L. Saunders","successor_named":true},"claim":"Clint Carnell resigned as Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"On November 9, 2021, by mutual agreement, the Board of Directors (the “Board”) of The Beauty Health Company (the “Company”) and Clint Carnell, the Company’s Chief Executive Officer and member of the Board, determined that Mr. Carnell would transition out of his roles as Chief Executive Officer and as a member of the Board, in each case, effective December 31, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001818093-21-000105","anchor_url":"https://secwatch.observer/filing/0001818093-21-000105#claim-bfdedb1d69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000105/0001818093-21-000105-index.htm"}]}